Arcus Biosciences (RCUS) Cash from Financing Activities (2017 - 2026)

Arcus Biosciences' Cash from Financing Activities history runs 10 years deep, the most recent figure standing at $3.0 million for Q1 2026.

• On a quarterly basis, Cash from Financing Activities fell 97.89% year-over-year to $3.0 million in Q1 2026; TTM through Mar 2026 was $349.0 million, a 83.68% increase from a year earlier, with the FY2025 full-year figure at $488.0 million, up 76.17% from the prior year.
• Cash from Financing Activities slipped to $3.0 million in Q1 2026 per RCUS's latest filing, from $286.0 million in the prior quarter.
• Across five years, Cash from Financing Activities topped out at $286.0 million in Q4 2025 and bottomed at -$2.0 million in Q4 2024.
• The 5-year median for Cash from Financing Activities is $8.0 million (2025), against an average of $49.1 million.
• Biggest YoY gain for Cash from Financing Activities was 22800.0% in 2024; the steepest drop was 166.67% in 2024.
• Year by year, Cash from Financing Activities stood at $11.0 million in 2022, then sank by 72.73% to $3.0 million in 2023, then tumbled by 166.67% to -$2.0 million in 2024, then jumped by 14400.0% to $286.0 million in 2025, then tumbled by 98.95% to $3.0 million in 2026.
• Per Business Quant, the three latest RCUS Cash from Financing Activities figures stand at $3.0 million (Q1 2026), $286.0 million (Q4 2025), and $8.0 million (Q3 2025).